A comprehensive review details how three FDA-approved therapies have dramatically improved spinal muscular atrophy outcomes ...

Fintel reports that on 12 October 2026, JP Morgan upgraded their outlook for Biogen (SWX:BIIB) from Neutral to Overweight. Biogen Inc., based in the United States, is a prominent biotechnology firm ...

France: A comparative effectiveness study in children with spinal muscular atrophy type 1 (SMA1) has found that gene therapy ...

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the biotechnology industry, ...

A recent study may reshape our understanding of brain evolution and open new avenues for studying neurological diseases.

The partnership has already brought in more than $200 million in philanthropic donations to help fund specific rare disease ...

For health systems, the burden extends well past the exam room. Despite the real clinical strides in cell and gene therapy — ...

"The brain may have been formed by the pressing together of two nervous systems."It was on October 17th that Live Science ...

JPMorgan analyst Chris Schott raises Biogen (BIIB) price target to $300 from $210, citing felzartamab and litifilimab ...

The Society for Pediatric Research's 2026 Mary Ellen Avery Award recognizes Wendy Chung's work building population-scale newborn screening systems, from spinal muscular atrophy pilots in New ...

Under the microscope, mitochondria inside healthy terminal Schwann cells form a web of interconnected branches, with tiny ...

Nucleic acid therapeutics, such as antisense oligonucleotides (ASOs), have emerged as promising platforms for treating a ...